643 filings
8-K
VXRT
Vaxart Inc
30 Apr 24
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
4:22pm
ARS
2023 FY
VXRT
Vaxart Inc
29 Apr 24
Annual report to shareholders
4:39pm
DEFA14A
VXRT
Vaxart Inc
29 Apr 24
Additional proxy soliciting materials
4:38pm
DEF 14A
VXRT
Vaxart Inc
Definitive proxy
29 Apr 24
4:37pm
PRE 14A
VXRT
Vaxart Inc
Preliminary proxy
18 Apr 24
4:10pm
S-8
pz3vkdh 9h9
14 Mar 24
Registration of securities for employees
4:56pm
8-K
ipqe1j
14 Mar 24
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
4:05pm
8-K
zehzofey5l3xs8p5
6 Mar 24
Vaxart, Inc. Appoints Steven Lo as New President, Chief Executive Officer, and Director
9:23am
8-K
yivz8l5d3ogekjvif5b7
29 Feb 24
Departure of Directors or Certain Officers
4:30pm
8-K
b50ye 0d5oix
15 Feb 24
Other Events
4:10pm
8-K/A
xg5zc2ifvv0b8hgcn
2 Feb 24
Departure of Directors or Certain Officers
4:49pm
8-K
q82wuxn
19 Jan 24
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
5:14pm
424B5
30tl763ep9qoskb
17 Jan 24
Prospectus supplement for primary offering
7:18pm
8-K
oik6581x54t5
16 Jan 24
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
5:18pm
8-K
yhdrchbg
16 Jan 24
Vaxart, Inc. Announces Management Change
9:19am
8-K
5cx3i6ry
2 Nov 23
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
4:11pm
8-K/A
52ejdwx0xppsu2at5xak
23 Oct 23
Submission of Matters to a Vote of Security Holders
5:09pm
8-K
l3vl37ok7wezifcf7
23 Oct 23
Amendments to Articles of Incorporation or Bylaws
5:01pm